Finance entity

Ginkgo Bioworks

Company DNA

Every one of those 1 sits in a single category, earnings. Ginkgo Bioworks is most often covered alongside Jason Kelly, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.2.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · Ginkgo Bioworks

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Ginkgo Bioworks

Every one of those 1 sits in a single category, earnings. Ginkgo Bioworks is most often covered alongside Jason Kelly, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.2. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. Ginkgo Bioworks appears in 1 tracked Finance story from February 27, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 91 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Ginkgo Bioworks. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Divestiture Completion

    Projected timeline for the formal separation of non-core biosecurity assets.

  2. Earnings Release

    Ginkgo reports a $0.38 EPS beat and releases full-year 2025 financial results.

  3. Strategic Pivot

    Company announces the divestiture of its biosecurity business and focus on Autonomous Labs.

  4. Pre-Earnings Analysis

    Market analysts provide insights into Ginkgo's upcoming results amid high expectations for cost-cutting updates.

Stories mentioning Ginkgo Bioworks 1

Earnings Neutral

Ginkgo Bioworks Surprises Markets with Significant $0.38 EPS Earnings Beat

Ginkgo Bioworks (NYSE: DNA) outperformed analyst expectations by $0.38 EPS in its latest quarterly report, signaling a potential shift in the company's financial trajectory. The results suggest that the synthetic biology leader's cost-cutting measures and platform scaling are beginning to deliver tangible bottom-line improvements.

2 sources

Ginkgo Bioworks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.